VHL Disease Types of Tumors
Find your care
Our specialists continually research and bring you the latest effective treatment options. Call 310-794-2858 to learn more about VHL care at UCLA Health.
Von Hippel-Lindau (VHL) Disease Types of Tumors / Manifestations
The specific types of tumors caused by VHL include the following:
- Brain and Spinal Cord Tumors
- Retinal Tumors
- Endolymphatic Sac Tumors (ELST)
- Renal Tumors and Cysts
- Pancreatic Tumors and Cysts
- Adrenal Tumors
- Reproductive Lesions
Below is information about the prevalence, presentation, symptoms, and management of various VHL disease manifestation by organ sites.
Brain and Spinal Cord
Prevalence
Central nervous system (CNS) hemangioblastomas (vascular tumors) are the most common brain and spinal cord tumors in patients with VHL disease, affecting up to 80% of patients.
Presentation
The average age of presentation is around 30 years old.
Possible symptoms
Symptoms depend on the location of the tumor. Hemangioblastomas frequently cause headaches, vomiting, poor muscle control and walking abnormally, pain, and sensory and motor loss.
Management
Many asymptomatic lesions can be observed. With symptoms, challenging locations, or with rapid growth, these may choose to be surgically removed. Occasionally embolization is used first for vascular lesions. For poor surgical candidates we have used stereotactic radiation therapy. Belzutifan, an oral medication, is emerging as an option to stabilize or shrink disease.
Retina
Prevalence
Retinal hemangioblastomas occur in up to 50-60% of patients with VHL disease.
Presentation
It is often the first manifestation of VHL disease since it frequently begins in childhood.
Possible symptoms
Severe visual deficits and blindness are possible.
Management
Many asymptomatic lesions can be observed. Management is determined based on the size, growth rate, swelling, and location of the lesion. Various management options are available including laser treatment, photodynamic therapy, and vitrectomy. Systemic and local therapy have been applied with some success.
Endolymphatic Sac Tumors (ELST)
Prevalence
Endolymphatic sac tumors occur in 10-15% VHL patients.
Presentation
Endolymphatic sac tumors present around the age of 30. Screening for these tumors can be challenging.
Possible symptoms
One sided vestibular symptoms can include partial or complete hearing loss, tinnitus, and ear fullness.
Management
Because audio-vestibular compromise can be irreversible and isn’t dependent on tumor size, most centers advocate for early surgical intervention. When tumors are large, pre-operative embolization has been described.
Renal Tumors and Cysts
Prevalence
60- 70% of people with VHL disease develop clear cell renal cell carcinoma, a type of kidney cancer. Renal cysts are present in over 50% of patients.
Presentation
The median age for presentation is in the 30-40’s. Patients generally have tumors in multiple locations within the kidney, often on both sides.
Possible symptoms
Small tumors do not cause pain. However, large tumors can cause flank pain, blood in the urine and an abdominal mass are possible. Renal cell carcinoma can spread to any organ.
Management
Renal cysts can be observed and rarely cause issues but can become solid unlike many sporadic cysts. Renal tumors are placed under active surveillance until a lesion hits 3 cm in size (solid component), at which time surgery is performed on that organ to remove all lesions and spare the kidney. Percutaneous treatments are considered for solitary lesions. Belzitufan, an oral medication, is emerging an option for select patients.
Pancreatic Tumors and Cysts
Prevalence
Pancreatic neuroendocrine tumors (pNET) occur in 15-20% of patients while cysts occur in 50-60% of patients with VHL disease.
Presentation
Pancreatic tumors occur at a median age of 30 and can have malignant behavior (can spread to other organs).
Possible symptoms
While these tumors are often asymptomatic, when large they can compress nearby organs and cause localized symptoms.
Management
Pancreatic cysts can be observed and rarely need to be drained. Cystadenomas are benign and are also observed unless they cause symptoms. Microcystic adenomas may be mistaken for pancreatic neuroendocrine tumors (pNET) and may need imaging or biopsy. pNETs are observed up to a certain size threshold (depending on the location) until they must be removed. Belzitufan, an oral medication, is emerging an option for select patients.
Adrenal Tumors
Prevalence
Pheochromocytomas (usually noncancerous tumors) occur in up to 20% of patients with VHL disease. Up to 5% of patients can get similar tumors outside the adrenal gland called paragangliomas (previously named extra-adrenal pheochromocytomas).
Presentation
These tumors present at an average age of 30 years but can present in childhood.
Possible symptoms
Paroxysmal or sustained hypertension (high blood pressure), palpitations, tachycardia (rapid heart rate over 100 beats per minute), headaches, sweating, pallor (pale appearance), and nausea. Pheochromocytomas can have malignant behavior and spread to other organs.
Management
Pheochromocytomas can present without symptoms when small. If asymptomatic, surveillance has been described. Endocrine blockage must be done before surgical procedures or childbirth. Surgery is recommended with growth or symptoms with partial adrenalectomy (when feasible) or total adrenalectomy.
Reproductive Lesions
Prevalence
Epididymal cystadenomas (noncancerous tumors) occur in up to 50% of men. Broad ligament cystadenomas are infrequent in women with unknown incidence.
Presentation
Cystadenomas of the epididymis may begin during teenage years. Broad ligament cystadenomas appear in women age 20-40.
Possible symptoms
Cystadenomas of the epididymis are often asymptomatic but can cause pain and pressure in the scrotum. Broad ligament cystadenomas are often asymptomatic but can cause pain and pressure in the pelvis.
Management
Cystadenomas are treated conservatively and rarely are removed as treatment could obstruct sperm flow. Broad ligament cystadenomas are rare, so the optimal management is currently unclear. While they can become large, cystadenomas are fairly slow growing and therefore they are often observed in young women of child-bearing potential.
Resources:
- “Clinical Characteristics and Patient Pathway for VHL Disease” video presented by Dr. Brian Shuch
- VHL Alliance is dedicated to improving diagnosis, treatment, and quality of life for individuals and families affected by Von Hippel-Lindau disease.
- National Cancer Institute’ PDQ Website